Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Merck
McKinsey
Medtronic
Express Scripts

Last Updated: February 7, 2023

Bremelanotide acetate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic sources for bremelanotide acetate and what is the scope of freedom to operate?

Bremelanotide acetate is the generic ingredient in one branded drug marketed by Palatin Technologies and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Bremelanotide acetate has seventy-nine patent family members in twenty-five countries.

One supplier is listed for this compound.

Summary for bremelanotide acetate
International Patents:79
US Patents:4
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
DailyMed Link:bremelanotide acetate at DailyMed

US Patents and Regulatory Information for bremelanotide acetate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Palatin Technologies VYLEESI (AUTOINJECTOR) bremelanotide acetate SOLUTION;SUBCUTANEOUS 210557-001 Jun 21, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Palatin Technologies VYLEESI (AUTOINJECTOR) bremelanotide acetate SOLUTION;SUBCUTANEOUS 210557-001 Jun 21, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Palatin Technologies VYLEESI (AUTOINJECTOR) bremelanotide acetate SOLUTION;SUBCUTANEOUS 210557-001 Jun 21, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for bremelanotide acetate

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2014071339 See Plans and Pricing
Australia 2005249474 See Plans and Pricing
Ukraine 118656 ЗАСТОСУВАННЯ БРЕМЕЛАНОТИДУ У ЛІКУВАННІ ЖІНОЧОЇ СЕКСУАЛЬНОЇ ДИСФУНКЦІЇ (BREMELANOTIDE THERAPY FOR FEMALE SEXUAL DYSFUNCTION) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Moodys
Dow
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.